La vendita allo scoperto per Cannara Biotech dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Cannara Biotech. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Cannara Biotech (OTC:LOVFF) Azioni, Report sulle vendite allo scoperto

Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .

CANNARA BIOTECH INC by Cannara Biotech Inc.

Cannara Biotech Inc

<p>RBC Capital  analyst Greg Pardy   maintains Strathcona Resources (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SCR#TSX">SCR</a>) with a Sector Perform and raises the price target from C$34 to C$36.</p>


News

Price Target

Analyst Ratings

TSX:SCR

RBC Capital Maintains Sector Perform on Strathcona Resources, Raises Price Target to C$36

WIIM

Disney shares are trading higher after the company announced it projects strong earnings growth especially in its ad supported streaming plans.

<p>Deep-pocketed investors have adopted a bearish approach towards Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in BIIB usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 15 extraordinary options activities for Biogen. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 26% leaning bullish and 66% bearish. Among these notable options, 2 are puts, totaling $80,703, and 13 are calls, amounting to $4,937,387.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $230.0 for Biogen, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Biogen options trades today is 1866.8 with a total volume of 4,855.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Biogen's big money trades within a strike price range of $110.0 to $230.0 over the last 30 days.</p>
<h3>Biogen 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731688345_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$1.5M</td>
<td>8.7K</td>
<td align="right">751</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$65.6</td>
<td>$65.5</td>
<td>$65.5</td>
<td>$110.00</td>
<td>$1.0M</td>
<td>8.7K</td>
<td align="right">896</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.6</td>
<td>$62.5</td>
<td>$62.5</td>
<td>$110.00</td>
<td>$625.0K</td>
<td>8.7K</td>
<td align="right">100</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$63.5</td>
<td>$62.6</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$375.6K</td>
<td>8.7K</td>
<td align="right">231</td>
</tr>
<tr>
<td>BIIB</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$62.6</td>
<td>$57.7</td>
<td>$62.6</td>
<td>$110.00</td>
<td>$319.2K</td>
<td>8.7K</td>
<td align="right">108</td>
</tr>
</tbody>
</table>
</p>
<h3>About Biogen</h3>
<p>Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.</p>
<p>After a thorough review of the options trading surrounding Biogen, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Current Position of Biogen</h3>
<ul>
<li>Currently trading with a volume of 610,232, the BIIB's price is down by -2.38%, now at $160.97. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 88 days.</li>
</ul>
<h3>What The Experts Say On Biogen</h3>
<p>In the last month, 5 experts released ratings on this stock with an average target price of $219.8.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Barclays continues to hold a Equal-Weight rating for Biogen, targeting a price of $180.<br />
&#x2A; An analyst from Morgan Stanley has revised its rating downward to Equal-Weight, adjusting the price target to $204.<br />
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $270.<br />
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Biogen, maintaining a target price of $255.<br />
&#x2A; Reflecting concerns, an analyst from Citigroup lowers its rating to Neutral with a new price target of $190.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Biogen options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

BIIB

Biogen Unusual Options Activity

<p>Deep-pocketed investors have adopted a bearish approach towards Synopsys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNPS#NASDAQ">SNPS</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in SNPS usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 8 extraordinary options activities for Synopsys. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 25% leaning bullish and 37% bearish. Among these notable options, 3 are puts, totaling $88,885, and 5 are calls, amounting to $268,163.</p>
<h3>Projected Price Targets</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $520.0 to $670.0 for Synopsys during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Synopsys stands at 140.67, with a total volume reaching 322.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Synopsys, situated within the strike price corridor from $520.0 to $670.0, throughout the last 30 days.</p>
<h3>Synopsys Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731688340_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$54.7</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$600.00</td>
<td>$76.3K</td>
<td align="right">13</td>
<td align="right">18</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$41.8</td>
<td>$36.7</td>
<td>$38.0</td>
<td>$520.00</td>
<td>$61.7K</td>
<td align="right">43</td>
<td align="right">0</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$3.5</td>
<td>$620.00</td>
<td>$46.2K</td>
<td align="right">367</td>
<td align="right">154</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$29.3</td>
<td>$28.4</td>
<td>$28.0</td>
<td>$540.00</td>
<td>$45.7K</td>
<td align="right">105</td>
<td align="right">5</td>
</tr>
<tr>
<td>SNPS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$54.5</td>
<td>$600.00</td>
<td>$38.1K</td>
<td align="right">13</td>
<td align="right">33</td>
</tr>
</tbody>
</table>
</p>
<h3>About Synopsys</h3>
<p>Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.</p>
<p>Having examined the options trading patterns of Synopsys, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Synopsys's Current Market Status</h3>
<ul>
<li>With a trading volume of 217,362, the price of SNPS is down by -3.59%, reaching $528.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 19 days from now.</li>
</ul>
<h3>Expert Opinions on Synopsys</h3>
<p>A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $658.75.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Loop Capital downgraded its action to Buy with a price target of $675.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Overweight rating on Synopsys with a target price of $670.<br />
&#x2A; In a cautious move, an analyst from Mizuho downgraded its rating to Outperform, setting a price target of $650.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $640. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Synopsys options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


SNPS

Synopsys Unusual Options Activity

<p>Financial giants have made a conspicuous bullish move on NIO. Our analysis of options history for NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) revealed 9 unusual trades.</p>
<p>Delving into the details, we found 44% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 5 were puts, with a value of $498,343, and 4 were calls, valued at $260,650.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3.0 and $17.5 for NIO, spanning the last three months.</p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in NIO's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to NIO's substantial trades, within a strike price spectrum from $3.0 to $17.5 over the preceding 30 days.</p>
<h3>NIO Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1731688335_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.97</td>
<td>$0.96</td>
<td>$0.96</td>
<td>$5.00</td>
<td>$219.3K</td>
<td>60.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$0.98</td>
<td>$0.96</td>
<td>$0.97</td>
<td>$5.00</td>
<td>$153.3K</td>
<td>60.2K</td>
<td>1.7K</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$1.41</td>
<td>$1.35</td>
<td>$1.4</td>
<td>$5.00</td>
<td>$140.0K</td>
<td>51.2K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.05</td>
<td>$13.0</td>
<td>$13.05</td>
<td>$17.50</td>
<td>$62.6K</td>
<td>75</td>
<td>48</td>
</tr>
<tr>
<td>NIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$1.43</td>
<td>$1.41</td>
<td>$1.43</td>
<td>$5.00</td>
<td>$42.1K</td>
<td>51.2K</td>
<td>1.3K</td>
</tr>
</tbody>
</table>
</p>
<h3>About NIO</h3>
<p>Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.</p>
<p>After a thorough review of the options trading surrounding NIO, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Present Market Standing of NIO</h3>
<ul>
<li>Trading volume stands at 19,370,337, with NIO's price down by -0.93%, positioned at $4.39.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 5 days.</li>
</ul>
<h3>What Analysts Are Saying About NIO</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $6.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Showing optimism, an analyst from Macquarie upgrades its rating to Outperform with a revised price target of $6. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for NIO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


This Is What Whales Are Betting On NIO

ELAN

Elanco Acquires Speke Manufacturing Facility For $25M, Securing Critical Supply Chain For Farm Animal Products Generating $160M-$180M Annually; Expected To Impact 2025 Adjusted EBITDA By $25M-$35M

<p>RBC Capital  analyst Logan Reich   reiterates Chipotle Mexican Grill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) with a Outperform and maintains $70 price target.</p>


Reiteration

RBC Capital Reiterates Outperform on Chipotle Mexican Grill, Maintains $70 Price Target

COIN

Coinbase shares are trading higher after the company recently announced it acquired on-chain payments platform Utopia Labs.

<p>Piper Sandler  analyst Brian Mullan   maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Neutral and raises the price target from $100 to $142.</p>


CAVA

Piper Sandler Maintains Neutral on Cava Group, Raises Price Target to $142

<p>Piper Sandler  analyst Alexander Goldfarb   maintains Hudson Pacific Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) with a Neutral and lowers the price target from $5 to $4.5.</p>


Piper Sandler Maintains Neutral on Hudson Pacific Properties, Lowers Price Target to $4.5

<p>RBC Capital  analyst Logan Reich   reiterates Starbucks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBUX#NASDAQ">SBUX</a>) with a Outperform and maintains $115 price target.</p>


SBUX

RBC Capital Reiterates Outperform on Starbucks, Maintains $115 Price Target

<p><strong>Zai Lab Ltd &#8211; ADR</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) shares are trading higher by 3.45% to $27.59 during Friday&#8217;s session. The company priced a $200 million public offering of 7,843,137 shares at <a href="https://www.benzinga.com/pressreleases/24/11/b41997659/zai-lab-announces-pricing-of-public-offering-of-american-depositary-shares">$25.50 per ADS</a>.</p>
<p>The offering is expected to close on November 18, subject to customary conditions. The company has also granted underwriters a 30-day option to purchase an additional 1,176,470 ADSs. </p>
<p>Net proceeds will be used for general corporate purposes. Goldman Sachs, Jefferies and Leerink Partners are the joint book-running managers for the offering.</p>
<p><strong>Read Also: <a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></strong></p>
<h2 class="wp-block-heading">How To Buy ZLAB Stock</h2>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instruments.</p>
<p>For example, in Zai Lab&#8217;s case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p>According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, ZLAB has a 52-week high of $36.50 and a 52-week low of $13.48.</p>


ZLAB

Why Zai Lab (ZLAB) Stock Is Trading Higher

<p>Raymond James  analyst Stephen Boland   maintains Pollard Banknote (TSX:<a class="ticker" href="https://www.benzinga.com/stock/PBL#TSX">PBL</a>) with a Outperform and raises the price target from C$44 to C$46.</p>


TSX:PBL

Raymond James Maintains Outperform on Pollard Banknote, Raises Price Target to C$46

<p><strong>Ulta Beauty, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) stock is moving lower Friday after <strong>Warren Buffet</strong>&#8216;s Berkshire Hathaway <a href="https://www.benzinga.com/markets/equities/24/11/41993666/warren-buffetts-berkshire-hathaway-slashes-apple-bofa-holdings-adds-dominos-pizza-in-q3">cut its position in the company. </a></p>
<p><strong>What To Know</strong>: Buffet&#8217;s Berkshire Hathaway cut nearly all of its position in the beauty brand, according to Berkshire&#8217;s latest 13F filing.</p>
<p>Berkshire initially reported holding 690,106 shares in Ulta in an August filing. The latest 13F filing, released Thursday, shows its position has been reduced to 24,203 shares, a 96% cut.</p>
<p>The filing also indicates new positions in <strong>Domino&#8217;s Pizza Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DPZ#NYSE">DPZ</a>) and <strong>Pool Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>). Berkshire acquired 1,277,256 shares of Domino&#8217;s, valued at approximately $549 million, and 404,057 shares of Pool Corp, worth about $152 million.</p>
<p>Furthermore, the filing shows that Berkshire continued to reduce its stake in <strong>Apple Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and <strong>Bank of America</strong> <strong>Corporation </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>). The August filing represents the company&#8217;s holdings as of June 30, while Thursday&#8217;s filing reports Berkshire&#8217;s holdings as of Sept. 30.</p>
<p><strong>How To Buy Ulta Stock</strong></p>
<p>Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. </p>
<p>For example, in Ulta Beauty's case, it is in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.</p>
<p><strong>Related Link: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41988194/trump-plans-to-erase-ev-tax-credit-analyst-says-its-net-bullish-calls-sell-off-wrong-knee-jerk-reaction">Trump Plans To Erase EV Tax Credit: Tesla Analyst Says It&#8217;s &#8216;Net Bullish,&#8217; Calls Sell-Off &#8216;Wrong Knee-Jerk Reaction&#8217;</a></strong></p>
<p><strong>ULTA Price Action:</strong> At the time of writing, Ulta stock is moving 2.39% lower at $373.24, Domino&#8217;s shares are moving 2.07% higher at $444.98, Pool stock is moving 2.52% higher at $366.51, Bank of America shares are trading 0.86% higher at $46.29, and Apple stock is moving 1.45% lower at $244.88 per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: Photo via Wikimedia Commons</em></p>


Movers

AAPL

POOL

ULTA

What's Going On With Ulta Beauty Shares Friday?

<p><strong>AST SpaceMobile, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) shares are moving lower on Friday after the company reported worse-than-expected 2024 third-quarter fiscal earnings after the bell <a href="https://www.benzinga.com//node/41994523">on Thursday</a>.</p>
<p><strong>What Happened:</strong> AST SpaceMobile shares fell about 13% after the company released earnings on Thursday. The earnings report included a loss of $1.10 per share, missing analyst estimates of a loss of 20 cents per share.</p>
<p>Furthermore, the company reported sales of $1.10 million, missing analyst estimates of $24.13 million. AST SpaceMobile reported other key pieces of financial data, including adjusted operating expenses of $45.3 million.</p>
<p>The company incurred about $374 million of gross capitalized property and equipment costs. It also reported $518.9 million in cash, cash equivalents and restricted cash. </p>
<p>Stepping back from finances, the company announced several key agreements, such as launch service agreements with Blue Origin for launches in 2025 and 2026. These agreements will enable the orbital deployment of up to 60 Block 2 BlueBird satellites.</p>
<p>The company&#8217;s coverage will initially target key markets, including the U.S., Japan, and Europe.</p>
<p>Additionally, the company achieved initial validation of its AST5000 ASIC chip, with the necessary infrastructure in place for commissioning in 2025. The combination of the new chip and the larger Block 2 array will support enhanced data transmission.</p>
<p>&#8220;We achieved many significant milestones in the quarter and continue our momentum with several key pieces now in place,&#8221; said <strong>Abel Avellan</strong>, founder, chairman and CEO of AST SpaceMobile. </p>
<p>&#8220;With the first five BlueBird satellites successfully unfolded and entering initial operations, our business is progressing according to plan. We&#8217;ve advanced our strategy across multiple efforts including progress on securing orbital launch capacity, growing our manufacturing capability, and expanding our customer ecosystem.&#8221;</p>
<p>Following the earnings report, UBS analyst <strong>Christopher Schoell</strong> maintained a Buy rating on AST SpaceMobile and raised the price target from&nbsp;$30&nbsp;to&nbsp;$31.</p>
<p><strong>Related Link: <a href="https://www.benzinga.com/24/11/41961161/musk-ramaswamy-headed-doge-department-will-be-an-incredibly-challenging-endeavor-says-ted-cruzshares-this-piece-o">Ted Cruz Says Running DOGE Won&#8217;t Be A Cake Walk, Offers Reading Advice To Elon Musk</a></strong></p>
<p><strong>ASTS Price Action:</strong> At the time of publication, AST SpaceMobile shares are moving 13.8% lower at $23.11, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: Photo via Company</em></p>


ASTS

What's Going On With AST SpaceMobile Stock Friday?

<p><strong>Spectrum Brands Holdings, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading lower on Friday.</a></p>
<p>The company reported fourth-quarter adjusted earnings per share of 97 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42004018/spectrum-brands-holdings-reports-fiscal-2024-fourth-quarter" rel="noreferrer noopener">missing the street view of $1.07</a>. Quarterly revenues were $773.7 million (+4.5%), beating the analyst consensus of $747.51 million.</p>
<p>Gross profit surged 17.8% to $288 million. Gross profit and margin increased due to productivity improvements, operational efficiencies, and inventory actions in the prior year, partially offset by ocean freight inflation.</p>
<p>Adjusted EBITDA decreased $42.6 million, driven by $32.5 million of lower investment income and $25.9 million of increased brand-focused investments, offset by gross profit improvements.</p>
<p>As of the fiscal year-end, the company reported a cash balance of $369 million and total liquidity of $860 million, including undrawn capacity on its cash flow revolver.</p>
<p>It had $578 million in outstanding debt, consisting of $496 million in senior unsecured notes and around $82 million in finance lease obligations, resulting in a net debt of approximately $209 million.</p>
<p><strong>Outlook: </strong>Spectrum Brands expects low single-digit growth in reported net sales in fiscal 2025 and adjusted EBITDA to increase by mid to high single-digits. Adjusted free cash flow is expected to be approximately<a href="https://www.benzinga.com/calendars/guidance"> 50% of adjusted EBITDA.</a></p>
<p>The company continues to target a long-term net leverage ratio of 2.0 &#8211; 2.5 times.</p>
<p>&#8220;I am excited about the upcoming year. Our focus during fiscal 2025 will be to continue the momentum we built in fiscal 2024 by investing in our brands to drive long-term growth, in innovation to expand core and adjacent categories, and in our operations to drive further cost improvement, quality and safety,&#8221; said David Maura, Chairman and Chief Executive Officer of Spectrum Brands.</p>
<p><strong>Price Action:</strong> SPB shares are trading lower by 4.78% to $89.38&nbsp;at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42012197/totalenergies-joins-bp-equinor-and-shell-in-500m-drive-for-global-energy-access\" target="_blank" rel="noreferrer noopener">TotalEnergies Joins BP, Equinor, And Shell In $500M Drive For Global Energy Access</a></strong></li>
</ul>


Earnings

Equities

Guidance

General

Spectrum Brands Stock Falls After Q4 Earnings Miss On Lower Investment Income: Details

<p>Raymond James  analyst Michael Barth   reiterates Enerflex (TSX:<a class="ticker" href="https://www.benzinga.com/stock/EFX#TSX">EFX</a>) with a Outperform and raises the price target from C$12 to C$13.75.</p>


TSX:EFX

Raymond James Reiterates Outperform on Enerflex, Raises Price Target to C$13.75

<p>RBC Capital  analyst Matthew McKellar   reiterates Smurfit WestRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) with a Outperform and maintains $58 price target.</p>


RBC Capital Reiterates Outperform on Smurfit WestRock, Maintains $58 Price Target

<p>Some large European and U.S. vaccine maker stocks have fallen in reaction to <strong>Robert F. Kennedy Jr.&#8217;s</strong> nomination to lead the&nbsp;Department of <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">Health and Human Services</a>.</p>
<p>Kennedy has been known to be against vaccines and has a track record of making false claims about vaccines, including the debunked idea that they cause autism. Scientific studies have <a target="_blank" href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower" rel="noreferrer noopener">debunked this theory</a>.</p>
<p>Also, given his critical stance on mainstream medical practices and vaccines, U.S. Food and Drug Administration (FDA) and National Institutes of Health (NIH) employees are worried about Kennedy <a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/42009107/robert-kennedy-poised-to-lead-health-and-human-services-why-fda-nih-officials-are-nervous" rel="noreferrer noopener">being in charge</a>.</p>
<p>Kennedy, who received Trump&#8217;s blessing to &#8220;<a target="_blank" href="https://www.benzinga.com/markets/cannabis/24/11/41828359/could-trumps-go-wild-on-health-invite-to-rfk-jr-drive-changes-for-cannabis-and-psychedelics" rel="noreferrer noopener">go wild on health</a>,&#8221; has stated intentions to overhaul various aspects of the federal health agencies.</p>
<p>In a post on social media, Kennedy <a target="_blank" href="https://x.com/RobertKennedyJr/status/1857198805919138235" rel="noreferrer noopener">said</a>, &#8220;Together we will clean up corruption, stop the revolving door between industry and government, and return our health agencies to their rich tradition of gold-standard, evidence-based science. I will provide Americans with transparency and access to all the data so they can make informed choices for themselves and their families.&#8221;</p>
<p>On Friday, the World Health Organization also defended vaccines describing them as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived <a href="https://www.benzinga.com/general/biotech/24/11/42006119/who-calls-vaccines-absolutely-critical-as-trumps-appointment-of-rfk-jr-pulls-pzifer-moderna-stocks-downhill" target="_blank" rel="noreferrer noopener">childhood without them</a>.</p>
<p>European vaccine player stocks declined, including&nbsp;<strong>GSK Plc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>), <strong>Valneva SE</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VALN#NASDAQ">VALN</a>), <strong>AstraZeneca Plc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), <strong><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41715307/biontech-variant-adapted-covid-19-vaccines-do-well-in-q3" rel="noreferrer noopener">BioNTech SE</a> </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>), and <strong>Sanofi SA</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>).</p>
<p>GSK stock fell after the company reported lower third-quarter sales, which was impacted by an 18% decline <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41624198/gsks-q3-earnings-hit-by-lower-than-expected-vaccine-sales-cautions-lower-revenue-for-2024" rel="noreferrer noopener">in vaccine sales</a>.</p>
<p>COVID-19 vaccine players <strong><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener">Moderna Inc</a></strong><a target="_blank" href="https://www.benzinga.com/general/biotech/24/11/41808252/moderna-q3-revenue-beats-on-updated-covid-19-vaccine-slashes-expenses-for-2024" rel="noreferrer noopener"> </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>), <strong><a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41596761/pfizer-q3-earnings-revenue-and-profit-on-heightened-demand-for-paxlovid-expects-10-billion-in-202" rel="noreferrer noopener">Pfizer Inc</a></strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), and BioNTech stock gained when the third quarter earnings surpassed estimates on increased vaccine demand.</p>
<p>Other vaccine players&#8217; stocks that are down include <strong>Merck &amp; Co Inc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) and <strong>Inovio Pharmaceuticals, Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>).</p>
<p><strong>Price Action: </strong>GSK stock is down 3.88% at $33.06, BNTX stock is down 5.18%, VALN stock is down 4.24%, AZN stock is down 2.08%, MRK stock is down 3.28%, INO stock is down 9.85% at last check Friday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/government/regulations/24/11/42011035/just-before-bidens-term-ends-taiwan-semiconductor-lands-6-6-billion-in-us-funding-to-build-advanced-chip-plants" target="_blank" rel="noreferrer noopener">Just Before Biden&#8217;s Term Ends, Taiwan Semiconductor Lands $6.6 Billion in US Funding to Build Advanced Chip Plants</a></strong></li>
</ul>
<p><em>Photo by Vladimka production via Shutterstock</em></p>


Biotech

Large Cap

Eurozone

Health Care

Trading Ideas

BNTX

MRNA

VALN

European And US Vaccine Stocks Are Under Pressure - Here's WHy

NDRA

ENDRA Life Sciences shares are trading lower. The company reported Q3 financial results.

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>Given that cannabis legalization is considered a growth trend, you may assume that there are few (if any) undervalued <a href="https://investorplace.com/industries/healthcare/cannabis/">cannabis stocks</a>. However, whether we&rsquo;re talking about undervalued in the traditional sense of the term, or undervalued using other metrics, there are plenty of names in the space that fit within this category.</p>



<p>There are companies either directly in the cannabis space, or in adjacent industries, that trade at low price-to-earnings multiples, or at a discount to book value. In addition, there are cannabis stocks to buy based upon the fact that they are undervalued relative to future potential.</p>



<p>What makes these types of cannabis stocks appealing is the fact that, given their under-appreciation by the market, small positive developments could drive big gains, given the potential for shares to surge both on improving fundamentals and price discovery.</p>



<p>This could especially prove to be the case if and when the U.S. federal marijuana laws are relaxed/reformed. With this in mind, let&rsquo;s dive in and take a look at the seven most undervalued cannabis stocks currently out there.</p>



<h2>Green Thumb Industries (GTBIF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-1-1-300x169.jpg" alt="cannabis stocks"><div>Source: Shutterstock</div></div>


<p><strong>Green Thumb Industries</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/gtbif-stock-quote/"><strong>GTBIF</strong></a>) is a leading multi-state operator. MSOs are companies that own and operate regulated cannabis operations across multiple U.S. states.  On a P/E and price-to-book basis, this cannabis purveyor does not appear undervalued.</p>



<p>GTBIF stock currently has a forward earnings multiple of 55.8, and trades at a 52% premium to book value. However, as analysts at Zuanic &amp; Associates (a cannabis stock research firm) argued last month, this <a href="https://seekingalpha.com/news/4030722-zuanic-bullish-on-cannabis-stocks-verano-marimed-planet-13-green-thumb">&ldquo;blue chip among the larger MSOs,&rdquo;</a> strong growth potential, irrespective of whenever federal marijuana law reforms ever happen.</p>



<p>Green Thumb shares have performed solidly in 2023, surging by nearly 20%. A <a href="https://www.marketwatch.com/story/curaleaf-and-canopy-growth-miss-q3-analyst-marks-while-ascend-wellness-beats-forecasts-d64ecb04">revenue and earning beat</a> last quarter may suggest strong operating performance will continue in the quarters ahead. The company&rsquo;s existing large presence would also likely give it a big first mover advantage if cannabis became fully legal on the U.S. federal level. </p>



<h2>Innovative Industrial Properties (IIPR)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-7-300x169.jpg" alt="A close-up shot of a marijuana growhouse. cannabis trends"><div>Source: Shutterstock</div></div>


<p><strong>Innovative Industrial Properties</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/iipr-stock-quote/"><strong>IIPR</strong></a>) is not directly in the cannabis business. Rather, this real estate investment trust  owns and leases out commercial property to state-licensed cannabis operators.</p>



<p>Using traditional metrics, IIPR stock is one of the undervalued cannabis stocks. This REIT trades at a price-to-funds from operations ratio of just 10.7, a discounted multiple compared to other industrial REITs. Admittedly, industry risks help to explain this valuation discrepancy.</p>



<p>However, if the Federal Reserve pivots on interest rates next year, IIPR, like other REITs, is likely to benefit from a re-expansion of its multiple. Revenue (<a href="https://www.businesswire.com/news/home/20231101542273/en/Innovative-Industrial-Properties-Reports-Third-Quarter-2023-Results">up nearly 10% last quarter</a>) and FFO (up 7.5% last quarter) also continue to grow at a steady clip. Potential upside from growth and lower interest rates, coupled with IIPR&rsquo;s 8.13% dividend, could be the recipe for some strong long-term total returns.</p>



<h2>Cannara Biotech (LOVFF)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-5-300x169.jpg" alt="aurora stock"><div>Source: Shutterstock</div></div>


<p><strong>Cannara Biotech</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/lovff-stock-quote/"><strong>LOVFF</strong></a>) is a cannabis stock that I&rsquo;ve previously noted as being <a href="https://investorplace.com/2023/08/7-smoking-hot-420-stocks-to-buy-in-2023/">undervalued and under-the-radar</a>. Shares in this Canada-based vertically-integrated cannabis firm trade for only 11.4 times trailing twelve month earnings. </p>



<p>LOVFF stock sports this low multiple, although the company&rsquo;s revenue increased by <a href="https://www.otcmarkets.com/otcapi/company/financial-report/389000/content">93%</a> last fiscal year (ending August 2023), with net income surging threefold during this same time frame. That&rsquo;s not to say, of course, that the current fiscal year will bring similar growth.</p>



<p>But even if Cannara&rsquo;s growth decelerates from here, greater awareness of this low-priced pot stock could result in outsized gains for shares. Keep in mind that Cannara is relatively less liquid than other names in the space. That may present challenges if you&rsquo;re looking to enter/exit a position. However, if you are aware of the risks, it&rsquo;s one of the top cannabis stocks to consider.</p>



<h2>WM Technology (MAPS)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-8-300x169.jpg" alt="Forget a 1-for-12 Split, Aurora Stock May as Well Go for 200"><div>Source: Shutterstock</div></div>


<p><strong>WM Technology</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/maps-stock-quote/"><strong>MAPS</strong></a>) is one of the more unique cannabis stocks. This company&rsquo;s shares make it a SaaS stock and a cannabis stock play. </p>



<p>After experiencing a big run-up in growth from the late-2010s through 2022, WM Technology has experienced a bit of a growth slump.</p>



<p>Yet despite entering a near-term rough patch, as <em>InvestorPlace&rsquo;s</em> Jeremy Flint pointed out in October, long-term growth potential with MAPS stock <a href="https://investorplace.com/2023/10/the-diy-cannabis-portfolio-7-stocks-from-seed-to-stem/">remains high</a>. According to Flint, the cannabis industry is expected to keep growing at a 25% annualized clip through the start of the next decade. </p>



<p>Such growth could be even stronger if federal cannabis law reforms arrive far sooner than currently anticipated. That&rsquo;s not all. <a href="https://seekingalpha.com/article/4649517-wm-technology-inc-maps-q3-2023-earnings-call-transcript">Operational strategy changes</a> discussed on WM&rsquo;s most recent earnings conference call could result in better-than-expected results in the quarters ahead. </p>



<h2>Marimed (MRMD)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/Marijuana1600-300x169.jpg" alt="Image of marijuana alongside three joints"><div>Source: Shutterstock</div></div>


<p><strong>Marimed</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/mrmd-stock-quote/"><strong>MRMD</strong></a>) is another cannabis stock that I&rsquo;ve previously noted as being undervalued in the traditional sense. However, since last discussing this particular MSO, the company has gone from reporting positive earnings to reporting net quarterly losses.</p>



<p>So, why do I consider it still one of the undervalued names in the space? As Zuanic &amp; Associates noted in the aforementioned research report, Marimed&rsquo;s swing to quarterly losses has to do with its ramping up of growth-related capital expenditures.</p>



<p>By keeping its foot on the growth gas pedal, Marimed could quickly scale into one of the top MSOs. Once the company is ready to take its foot off the pedal, this could result in a dramatic increase in profits. This in turn could result in a big jump for MRMD shares. As also noted before, Marimed could be <a href="https://investorplace.com/2023/06/7-otc-stocks-to-buy-with-boatloads-of-potential/">an ideal acquisition candidate</a>, whenever federal cannabis laws finally change.</p>



<h2>Newlake Capital Partners (NLCP)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-9-300x169.jpg" alt="A close-up shot of hands holding a grinder with cannabis buds in the background representing aurora stock."><div>Source: Shutterstock</div></div>


<p>Just like IIPR, <strong>Newlake Capital Partners</strong> (OTCMKTS:<a href="https://investorplace.com/stock-quotes/nlcp-stock-quote/"><strong>NLCP</strong></a>) is a cannabis REIT, owning and leasing out space to state-licensed cannabis producers. If IIPR is one of the undervalued cannabis stocks, one could say that Newlake is one of the deep value cannabis stocks.</p>



<p>Yes, NLCP stock trades at a discount, because of perceptions that it is a riskier cannabis REIT. However, as a <em>Seeking Alpha</em> commentator recently argued, this valuation discrepancy <a href="https://seekingalpha.com/article/4653246-newlake-capital-partners-one-safest-double-digit-dividend-reits">may more than cover the increased risks</a>.</p>



<p>Based on valuation metrics, it&rsquo;s easy to agree with this commentator&rsquo;s take. NLCP trades at a P/FFO ratio of 7.9, well below that of IIPR. This REIT also trades at a 30% discount to book value, and sports a double-digit dividend yield (11.22%). The reporting of &ldquo;less bad&rdquo; results, lower interest rates, and cannabis law reforms are all catalysts that could drive an eventual big comeback for NLCP.</p>



<h2>Turning Point Brands (TPB)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/aurora-cannabis-stock-6-300x169.jpg" alt="cannabis stocks, With America Turning Green Things Only Can Get Better for Aurora Stock"><div>Source: Shutterstock</div></div>


<p>Back in April, I called <strong>Turning Point Brands</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/tpb-stock-quote/"><strong>TPB</strong></a>) <a href="https://investorplace.com/2023/04/the-7-best-cannabis-stocks-to-buy-for-april-2023/">one of the top cannabis stocks</a>. Even as TPB has delivered a mixed price performance since then, I still consider it one of the cannabis stocks to buy. This is not a cannabis pure play.</p>



<p>Turning Point is primarily a tobacco company, with Stoker&rsquo;s smokeless tobacco its most prominent brand. However, as the U.S. distributor/marketer of Zig Zag rolling papers, it has high exposure (pun intended) to the cannabis sector. Zig Zag sales <a href="https://www.turningpointbrands.com/investor-relations/news/news-details/2023/Turning-Point-Brands-Announces-Third-Quarter-2023-Results-and-Closing-of-New-ABL-Facility/default.aspx">have entered a slump recently</a>, and the main play with TPB stock now has more to do with the continued growth of Stoker&rsquo;s.</p>



<p>Still, if Turning Points pulls off a turnaround of the Zig Zag segment, low-priced TPB (trading for just 8.8 times earnings) could surge substantially, thanks to both profitability growth and multiple expansion.</p>



<p><em>On the date of publication, Thomas Niel&nbsp;did not hold (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.</em></p>
<div><p>Thomas Niel, contributor for InvestorPlace.com, has been writing single-stock analysis for web-based publications since 2016.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771234">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771244">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/05/secret-income-blueprint-of-the-one-percent/?cid=MKT730394&amp;eid=MKT771242">The Rich Use This Income Secret (NOT Dividends) Far More Than Regular Investors</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2023/12/the-7-most-undervalued-cannabis-stocks-to-buy-in-december/">The 7 Most Undervalued Cannabis Stocks to Buy in December</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

The 7 Most Undervalued Cannabis Stocks to Buy in December

Cannara Biotech, Inc. (TSE:LOVE) has released an update. Cannara Biotech Inc. has reported a significant increase in financial results for Q2 2024,...

Cannara Biotech Boasts Strong Q2 Growth

Cannara Biotech reports Q2 results

Cannara Biotech (TSE:LOVE) has released an update. Cannara Biotech Inc. has reported a significant increase in net revenues to $19.5 million for Q3...

Cannara Biotech's Revenue Soars in Q3 2024

Cannara Biotech GAAP EPS of C$0.02, revenue of C$19.5M

Cannara Biotech (TSE:LOVE) has released an update. Cannara Biotech Inc. has reached a new pinnacle by achieving a record national market share of 3...

Comments

Cannara Biotech

Vendite allo scoperto

Cannara Biotech (OTC:LOVFF) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO